The specialty pharmacy market is moving fast. Large players are absorbing independent locations, direct-to-patient platforms are growing at a pace most pharmacists haven’t registered yet, and the clinical gap left behind each acquisition is widening. That gap is real opportunity, but only for pharmacists who recognize it and move deliberately.
What Just Happened This Month
April 2026 delivered three specific developments that collectively describe where specialty pharmacy is heading.
OneroRx, an integrated pharmacy serving underserved markets, completed its acquisition of 14 NuCara Pharmacy and 10 Home Medical Equipment locations in Iowa and Minnesota on April 2, 2026, bringing its total to 91 locations across eight Midwest states and employing over 1,000 team members. Through this acquisition, OneroRx became the largest rural-based pharmacy in Iowa, filling more than 5 million prescriptions per year.
The NuCara story has a harder edge than the press release conveys. Four Iowa NuCara locations closed entirely, including the only pharmacy in the town of Traer, leaving 1,500 residents without pharmacy services for miles. NuCara’s parent company, NuDak Ventures, faced a state lawsuit alleging it owes more than $22 million to Iowa’s Health Department.
OneroRx stepped in and absorbed 14 of those locations. But Traer, Conrad, Ackley, and Zearing lost their pharmacies entirely. The corporate acquisition solved part of the problem. It left the rest as white space.
Simultaneously, on the rare disease side: Anovo serves as Ascendis Pharma’s exclusive specialty pharmacy partner for the recent launch of YUVIWEL, a new once-weekly therapy for achondroplasia, supporting patients with personalized care and access coordination. Orsini was named the single-source specialty pharmacy partner for Glaukos’ Epioxa, an FDA-approved therapy for keratoconus that received accelerated approval in October 2025 and offers an incision-free alternative to traditional corneal cross-linking. A new specialty pharmacy program also launched in Bowling Green, Kentucky, through a partnership between Med Center Health and Clearway Health, designed to ensure patients with complex and chronic illnesses have equitable access to vital medications.
Three stories from one week. A rural acquisition leaving gaps. New rare disease therapies locked to single-source specialty partners. A health system building specialty infrastructure from scratch because patient need has outpaced existing supply. These are not isolated events. They describe the current state of the market.
The Market Behind the Headlines
In 2025, retail, mail, long-term care, and specialty pharmacies collectively dispensed an estimated $293.4 billion in specialty pharmaceuticals, a 9.6% increase over 2024. The three largest specialty pharmacies accounted for two-thirds of total specialty prescription revenues. All three are owned by vertically integrated organizations that also own a PBM.
Two-thirds of all specialty drug dispensing controlled by three players, each embedded in a vertically integrated payer structure. The specialty market is not fragmented. It is concentrated, and it keeps concentrating.
The specialty pharmaceuticals market grew from $394 billion in 2025 to $434 billion in 2026, with a projected CAGR of 10.5% through 2032. Specialty therapies represent approximately 75% of the 7,000 drugs currently under development. As of October 2025, 46 cell and gene therapies had received FDA approval, with more than 500 additional therapies in the pipeline.
The pipeline isn’t slowing. More therapies mean more patients who need what specialty pharmacy provides, clinical support, adherence monitoring, prior authorization navigation, complex injection counseling, and the kind of relationship that sustains patients through difficult, high-cost treatment journeys.
The Direct-to-Patient Signal Pharmacists Cannot Ignore
The other major story in April was the direct-to-patient (DTP) channel expanding aggressively.
PHIL Inc., a healthcare technology company that helps pharmaceutical manufacturers streamline medication access for patients, announced a significant expansion of its cash dispense capabilities. After seeing 20x growth in cash dispenses in 2025, PHIL introduced enhanced capabilities to support an all-time-high prescription volume while building capacity for significant future growth. The company operates a nationwide network licensed in all 50 states, serving over a million patients each year.
Robert Schumaker, VP of Pharmacy Network & Wholesale Operations at PHIL, described the new capabilities as “game changing,” adding that the investment positions the company to meet “the explosive growth of direct-to-patient access.”
A 20x increase in cash dispensing in a single year is not incremental growth. It describes a structural shift in how specialty drugs reach patients. The DTP model, where pharmaceutical manufacturers route prescriptions directly to patients via mail through platforms like PHIL, bypassing traditional pharmacy channels, removes the pharmacist from the access equation unless the pharmacist brings clinical value that DTP cannot replicate.
Major players like Eli Lilly (LillyDirect) and Novo Nordisk have paved the way for direct-to-patient care. The next wave of DTP combines a seamless digital experience with increased affordability to help more patients start and stay on therapy.
Dispensing alone does not compete with that infrastructure. Clinical relationships do.
The Consolidation Paradox: Concentration Creates Gaps
Here is the business insight most pharmacists miss when they watch consolidation unfold: every time a large entity absorbs a rural or community specialty pharmacy, something happens to the local relationship infrastructure. It doesn’t transfer. It dissolves.
The patients who used to call a pharmacist they knew personally by name, the one who remembered their adherence struggles, knew their prescriber, understood their family situation, now interact with a centralized call center or an automated refill system owned by a corporate entity three states away. The dispensing happens. The clinical relationship doesn’t.
The Bowling Green partnership between Med Center Health and Clearway Health specifically cited equitable access to vital medications and “the ongoing care and support needed to manage complex medical conditions” as its core mission. Future plans include expanding specialty pharmacy services to additional clinic sites and opening a new dedicated specialty pharmacy space.
That framing is significant. A health system built a specialty pharmacy program from scratch because the existing market left a care coordination gap. Pharmacists who build that same model, specialty-capable, locally embedded, clinically oriented, fill the same gap the corporate consolidation creates in community after community.
What the Map Looks Like Right Now
The number of accredited specialty pharmacy locations grew by only 3% in 2025 but remains more than five times larger than the 2015 figure. Economic power, however, remains concentrated among a small group of PBM-affiliated entities.
PBM/health plan-owned specialty pharmacies maintain a significant advantage in accessing limited distribution drugs. A large proportion of specialty drugs launch with a limited network, networks that are often becoming smaller and more exclusive to support complex rare disease therapies. This structural advantage poses a real challenge for independent specialty pharmacies competing for limited distribution contracts.
That sounds like a ceiling. But it isn’t, because the PBM-affiliated model optimizes for formulary compliance and cost control, not for local clinical relationships. And the patients managing multiple sclerosis, inflammatory conditions, rare diseases, HIV, and complex oncology regimens in community settings need a pharmacist who knows them, not a national call center.
Your Action This Week
Review your current patient panel for specialty-eligible conditions. Multiple sclerosis. Rheumatoid arthritis and other inflammatory conditions. HIV. Oncology. Rare diseases. Patients managing GLP-1 therapy with concurrent biologics. Patients on high cost injectables who receive them by mail with no clinical contact.
For each of those patients, ask one question: who is providing clinical support right now?
If the answer is “nobody” or “a mail pharmacy they’ve never met”, that is your opening.
The tools exist to build a specialty services model in a community pharmacy. Accreditation pathways through URAC and ACHC establish the credibility needed to access limited distribution networks. Clearway Health and similar health system partnership models create infrastructure for specialty services without requiring standalone specialty pharmacy licensure. And the clinical training, injection counseling, biologic adherence monitoring, irAE surveillance, prior authorization appeals, is exactly what PharmD training prepares you to deliver.
The consolidation wave creates the gap. The direct-to-patient channel widens it. A pharmacist with specialty training and community ties is positioned to fill it better than any corporate entity that absorbed the previous provider.
The pharmacies that move now, before the gap gets wider and more competitive, will define the specialty access landscape in their communities for the next decade.
Sources: OneroRx Press Release (NuCara Acquisition, April 2, 2026), KCRG / Cedar Rapids Today (NuCara Pharmacy Closures, Iowa, April 2026), Chain Drug Review (OneroRx-NuCara Acquisition), Access Market Intelligence (Specialty Pharmacy News Roundup Pre-Asembia, April 21, 2026), PHIL Inc. Press Release via Yahoo Finance / PharmiWeb (Cash Dispense Expansion, April 2026), Drug Channels Institute (Top 15 Specialty Pharmacies of 2025, April 2026), Drug Channels Institute (Top 15 U.S. Pharmacies of 2025, March 2026), IntuitionLabs (Specialty Pharmacy Key Players & Trends, March 2026), Trilliant Health (2026 Specialty Pharmacy Market Report), SpecialtyRx / Definitive Healthcare (Specialty Pharmacy Market Trends 2025)
